Oxford Cannabinoid Technologies emerged from university research project into potential treatments.
Oxford Cannabinoid Technologies, a biotech company developing medicines that mimic the painkilling effects of cannabis, is to float on the main London market on Friday.
OCT, which started up four years ago with a venture-capital funded programme of research into medical marijuana at Oxford university, will raise £16.5m from the initial public offering, which is heavily oversubscribed. Its valuation after the listing is expected to be about £51.5m.
Read the full FT story here.
Date posted: 18 May 2021
Article tag: Oxford Cannabinoid Technologies
Share